Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2026)

Tarsus Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Finished Goods rose 51.47% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 51.47% YoY), while the FY2025 annual figure was $3.0 million, up 47.66% from the prior year.
• Finished Goods for Q1 2026 stood at $2.9 million, down from $3.0 million in the prior quarter.
• The five-year high for Finished Goods was $3.0 million in Q4 2025, with the low at $182000.0 in Q4 2023.
• The 4-year median for Finished Goods is $2.0 million (2024), against an average of $1.8 million.
• The sharpest annual moves came in 2024 and 2025: Finished Goods surged 1002.2% in 2024, then jumped 47.66% in 2025.
• Tarsus Pharmaceuticals' Finished Goods stood at $182000.0 in 2023, then soared by 1002.2% to $2.0 million in 2024, then soared by 47.66% to $3.0 million in 2025, then decreased by 0.74% to $2.9 million in 2026.
• Business Quant data shows TARS's Finished Goods at $2.9 million in Q1 2026, $3.0 million in Q4 2025, and $2.8 million in Q3 2025.